Phase 3 Clinical Trials With Primary Completion Dates in April 2019

This is a list of Phase 3 trials with primary completion dates in April 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ACSTAcasti Pharma, Inc.2019-04-01Phase 3NCT03398005A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)
ACSTAcasti Pharma, Inc.2019-04-01Phase 3NCT03361501A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)
ATNXAthenex, Inc.2019-04-01Phase 3NCT03285490A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (AK004)
ATNXAthenex, Inc.2019-04-01Phase 3NCT03285477A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
IRWDIronwood Pharmaceuticals, Inc.2019-04-01Phase 3NCT03573908A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
OBSVObsEva SA2019-04-01Phase 3NCT03070951Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
SNYSanofi2019-04-01Phase 3NCT03700242Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year